Centessa Pharmaceuticals PLC

Centessa Pharmaceuticals — Investor Presentation (August 2023)

29 slides from Centessa Pharmaceuticals's investor presentation, Aug 14, 2023

  1. Slide 1: Corporate Overview August 2023

    Corporate Overview AUGUST 2023 Asset-Centric. Patient-Centric.

  2. Slide 2: Disclaimer and forward-looking statements

    This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as adv

  3. Slide 3: Discovering and developing medicines that are transformational for patients

    Discovering and developing medicines that are transformational for patients Multiple potential blockbuster assets Cash runway into 2026 enables multiple clinical readouts World-class R&D team 3 Note: The Company reported $303.6 million in cash, cash equivalents and short-term investments as of June

  4. Slide 4: We are a transformational pharmaceutical company fueling an innovative pipeline

    DIFFERENTIATION We are a transformational pharmaceutical company fueling an innovative pipeline 4 Lead Assets Disease Estimated Market Size* SerpinPC Hemophilia B $2B+1 PD-L1xCD47 LockBody® (LB101) Solid Tumors $10B1 PD-L1xCD3 LockBody® (LB206) Solid Tumors $10B1 ORX750 Narcolepsy (NT1) and other sl

  5. Slide 5: Cash runway into 2026 enables multiple clinical readouts

    5 CASH RUNWAY INTO 2026 ENABLES MULTIPLE CLINICAL READOUTS Centessa has multiple early-stage programs including additional orexin agonists and discovery-stage programs not reflected on this slide. INNOVATIVE PIPELINE Potential first-in-class/ best-in-class medicines for patients ASSET DISEASE MECHAN

  6. Slide 6: Team with deep R&D experience and focused on execution

    LEADERSHIP Team with deep R&D experience and focused on execution 6 DAVID CHAO PhD Chief Administrative Officer TIA BUSH Chief Technology & Quality Officer SAURABH SAHA MD PhD Chief Executive Officer ANTOINE YVER MD MSc EVP & Chairman of Development DAVID GRAINGER PhD Chief Innovation Officer IQBAL

  7. Slide 7: SerpinPC in Hemophilia

    SerpinPC in Hemophilia YK CENTESSA

  8. Slide 8: SerpinPC: Novel, subcutaneously administered biologic inhibitor of APC

    SerpinPC: Novel, subcutaneously administered biologic inhibitor of APC 8 Novel MoA; Showed significant reduction in bleeding2 Shown to have a favorable safety and well tolerated profile2; No thrombosis observed2 In registrational studies for the treatment of hemophilia B HEMOPHILIA B UNMET NEED Inco

  9. Slide 9: SerpinPC: Designed to exploit novel pharmacology to prevent and reduce bleeding

    SerpinPC: Designed to exploit novel pharmacology to prevent and reduce bleeding 9 Primary APC is the target of SerpinPC All beds Spontaneous joint bleeds • Human genetic target validation • Engineered to specifically inhibit APC • Inhibition of APC increases thrombin • Feedback loop designed to prev

  10. Slide 10: SerpinPC Phase 2a Study: robust and highly differentiating clinical data

    10 SerpinPC Phase 2a Study Robust and highly differentiating clinical data With total exposure of over 40 patient-years across multiple dosing regimens, Phase 2a data showed: The top graph shows the D-dimer results in the 17 subjects who had results < 500 and the 5 subjects who had non-consecutive r

  11. Slide 11: SerpinPC Phase 2a Study: favorable tolerability profile

    11 SerpinPC Phase 2a Study Robust and highly differentiating clinical data With total exposure of over 40 patient-years across multiple dosing regimens, Phase 2a data showed: 1. Phase 2a study data from Part 3 and Part 4 were presented in oral presentations at ASH and EAHAD in December 2022 and Febr

  12. Slide 12: SerpinPC Phase 2a Study: reduction in bleeding

    12 SerpinPC Phase 2a Study Robust and highly differentiating clinical data With total exposure of over 40 patient-years across multiple dosing regimens, Phase 2a data showed: SerpinPC reduced median all-bleeds ABR by 93% at highest dose tested ABR is annualized bleeding rate. 1. Phase 2a study data

  13. Slide 13: SerpinPC in registrational studies for hemophilia B

    13 SerpinPC In registrational studies for hemophilia B, with or without inhibitors SerpinPC has not been approved by the FDA or any other regulatory authority. Granted Fast Track designation by the FDA in May 2023 Granted Orphan Drug Designation by the FDA in Sept. 2022

  14. Slide 14: LB101 and LB206 in Solid Tumors

    LB101 and LB206 in Solid Tumors 14

  15. Slide 15: LockBody: It's all about the hinge

    LockBody® “It’s all about the hinge” LockBody Technology Platform: Aims to redefine immuno-oncology treatment 15 Novel pharmacology focused on human IgG-derived hinges susceptible to natural intra-tumoral hinge cleavage Designed as single agent systemic treatment to selectively drive potent effector

  16. Slide 16: LB101: A novel, conditionally tetravalent PD-L1xCD47 bispecific antibody

    LB101: A novel, conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody 16 Tumor Unlocking: IgG1 hinges susceptible to cleavage in diseased tissue by various natural processes Peripheral Stability: IgG1 hinges naturally resistant to cleavage in serum Constitutive Fabs: PD-L1 Domains Full

  17. Slide 17: LB101 showed improved efficacy and durability over atezolizumab in mouse model

    LB101 showed improved efficacy and durability over atezolizumab in a difficult-to-treat mouse model while being well tolerated 17 In vivo study showed systemically delivered LB101 exhibited significant tumor regression In vivo study showed LB101 was well tolerated with no weight loss Note: MC38 hPD-

  18. Slide 18: LB101 favorable safety and tolerability in non-human primates

    LB101 shown to have favorable safety and tolerability profile in non- human primates up to 50 mg/kg weekly x 4 weeks 18 In-vivo: LB101 delivered IV at 5, 20, 50mg/kg (q7d x 4) in non-human primates • Human IgG1-like PK • No adverse observations - No anemia or thrombocytopenia - No changes in patholo

  19. Slide 19: LB101 LockBody in Phase 1/2a Clinical Trial

    19 LB101 LockBody in Phase 1/2a Clinical Trial Phase 1/2a Clinical Trial • Open-label, multicenter, dose escalation with expansion cohorts • Part 1: LB101 monotherapy in subjects with selected, advanced solid tumors; determine recommended dose(s) for expansion (Part 2) • Part 2: Design depends on Pa

  20. Slide 20: LB206: A novel, conditionally bivalent PD-L1xCD3 bispecific antibody

    LB206: A novel, conditionally bivalent PD-L1xCD3 bispecific monoclonal antibody 20 Tumor Unlocking: IgG1 hinges susceptible to cleavage in diseased tissue by various natural processes Peripheral Stability: IgG1 hinges naturally resistant to cleavage in serum Constitutive Fabs: PD-L1 Domain Fully hum

  21. Slide 21: LB206: Designed to concentrate and drive potent CD3 activity in solid tumors

    Tumor Unlocking IgG1 hinges susceptible to cleavage in diseased tissue by various natural processes Peripheral Stability IgG1 hinges naturally resistant to cleavage in serum Deactivation Second cleaving event terminates CD3 activity LB206: Designed to concentrate and drive potent CD3 activity in sol

  22. Slide 22: LB206: In vivo data demonstrated significant tumor regressions

    22 0 50 100 150 200 250 300 350 0 3 6 9 12 15 18 21 M e a n t u m o r v o l. ( m m 3 ) Time on treatment (days) IgG1 Control LB206 8.5 mg/kg (n=8) 4.5 mg/kg (n=8) 8.5 mg/kg (n=8) Dose administered 1 Mean body weight values for Day 0 and Day 20 within +/- 6% range for each of the four groups. Potent

  23. Slide 23: LB206: In vivo follow-up experiment showed regression of large tumors

    23 LB206: In vivo data from follow-up experiment demonstrated regression of large tumors in a difficult-to-treat mouse model 0 100 200 300 400 500 600 0 3 6 9 12 15 18 21 0 100 200 300 400 500 600 0 3 6 9 12 15 18 21 Time on treatment (days) Time on treatment (days) LB206 8.5 mg/kg (n=5) LB206 1.5 m

  24. Slide 24: ORX750 in Narcolepsy

    ORX750 in Narcolepsy 24

  25. Slide 25: ORX750: Orally administered, selective orexin receptor-2 agonist

    Highly validated human target with clinical proof of concept in NT1 Exploring follow-up orexin agonists for potential expansion opportunities into sleep disorders and broader neurological indications 25 ORX750: Orally administered, selective orexin receptor-2 (OX2R) agonist High unmet need EDS is ex

  26. Slide 26: Structure-based drug design enabled discovery of ORX750

    Structure-based drug design has enabled the discovery of ORX750 as potential orexin signaling ‘replacement therapy’ for NT1, with potential indication expansion beyond NT1 Illustration of OX2R structure bound to prototype small molecule orexin agonist (shown in purple) 26

  27. Slide 27: ORX750 increased wakefulness in NT1 model and wild type mice

    ORX750 increased wakefulness in NT1 model and wild type mice 27 NT1 model mice *P < 0.05 vs. 0 mg/kg • ORX750 increased time awake in an NT1 mouse model, showing maximal wake promotion (ceiling effect) at doses shown • Wake % time in wild type mice showed a dose- related response which supports pote

  28. Slide 28: Centessa is fueling multiple pathways to value creation

    Centessa is fueling multiple pathways to value creation 28 Multiple potential blockbuster assets Cash runway into 2026 enables multiple clinical readouts World-class R&D team Note: The Company reported $303.6 million in cash, cash equivalents and short-term investments as of June 30, 2023. In additi

  29. Slide 29: Centessa Pharmaceuticals

    << CENTESSA PHARMACEUTICALS

Centessa Pharmaceuticals — Investor Presentation (August 2023) on 6ix